Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 897-901 , June 2008

Plasminogen activator inhibitor in human tears after laser refractive surgery

,Accepted 27 February 2008.

References 

  1. Pop M, Payette Y. Photorefractive keratectomy versus laser in situ keratomileusis; a control-matched study. Ophthalmology. 2000;107:251–257
  2. Farah SG, Azar DT, Gurdal C, Wong J. Laser in situ keratomileusis: literature review of a developing technique. J Cataract Refract Surg. 1998;24:989–1006
  3. Rajan MS, Jaycock P, O'Brart D, Ham Nystrom H, Marshall J. A long-term study of photorefractive keratectomy; 12-year follow-up. Ophthalmology. 2004;111:1813–1824
  4. Chan TK, Ashraf MF, Azar DT. Photorefractive keratectomy (PRK) outcomes and complications. In:  Azar DT,  Steinert RF,  Stark WJ editor. Excimer Laser Phototherapeutic Keratectomy. Baltimore, MD: Williams & Wilkins; 1997;p. 157–173
  5. Hadden OB, Ring CP, Morris AT, Elder MJ. Visual, refractive, and subjective outcomes after photorefractive keratectomy for myopia of 6 to 10 diopters using the Nidek laser. J Cataract Refract Surg. 1999;25:936–942
  6. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem. 1990;23:197–211
  7. Hayashi K, Sueishi K. Fibrinolytic activity and species of plasminogen activator in human tears. Exp Eye Res. 1988;46:131–137
  8. Wang H-M, Berman M, Law M. Latent and active plasminogen activator in corneal ulceration. Invest Ophthalmol Vis Sci. 1985;26:511–524Available at: http://www.iovs.org/cgi/reprint/26/4/511Accessed March 11, 2008
  9. Csutak A, Tőzsér J, Békési L, Hassan Z, Berta A, Silver DM. Plasminogen activator activity in tears after excimer laser photorefractive keratectomy. Invest Ophthalmol Vis Sci. 2000;41:3743–3747Available at: http://www.iovs.org/cgi/reprint/41/12/3743Accessed March 11, 2008
  10. Grøndahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound re-epithelialization in vivo. J Invest Dermatol. 1988;90:790–795Available at: http://www.nature.com/jid/journal/v90/n6/pdf/5613632a.pdfAccessed March 11, 2008
  11. Schäfer BM, Marier K, Eickhoff U, Todd RF, Kramer MD. Plasminogen activation in healing human wounds. Am J Pathol. 1994;144:1269–1280Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid=1887462&blobtype=pdfAccessed March 11, 2008
  12. Csutak A, Silver DM, Tőzsér J, Facskó A, Berta A. Plasminogen activator activity and inhibition in rabbit tears after photorefractive keratectomy. Exp Eye Res. 2003;77:675–680
  13. Lohmann CP, Marshall J. Plasmin- and plasminogen-activator inhibitors after excimer laser photorefractive keratectomy: new concept in prevention of postoperative myopic regression and haze. Refract Corneal Surg. 1993;9:300–302
  14. O'Brart DPS, Lohmann CP, Klonos G, Corbett MC, Pollock WST, Kerr-Muir MG, et al. The effects of topical corticosteroids and plasmin inhibitors on refractive outcome, haze, and visual performance after photorefractive keratectomy; a prospective, randomized, observer-masked study. Ophthalmology. 1994;101:1565–1574
  15. Tervo T, Tervo K, van Setten G-B, Virtanen I, Tarkkanen A. Plasminogen activator and its inhibitor in the experimental corneal wound. Exp Eye Res. 1989;48:445–449
  16. Tözsér J, Berta A. Plasminogen activator inhibitors in human tears. Acta Ophthalmol (Copenh). 1991;69:426–431
  17. Williams DL, Risse B, Kim S, Saunders D, Orlin S, Baker MS, et al. Plasminogen activator inhibitor type 2 in human corneal epithelium. Invest Ophthalmol Vis Sci. 1999;40:1669–1675Available at: http://www.iovs.org/cgi/reprint/40/8/1669Accessed March 11, 2008
  18. Hanna KD, Pouliquen YM, Savoldelli M, Fantes F, Thompson KP, Waring GO, et al. Corneal wound healing in monkeys 18 months after excimer laser photorefractive keratectomy. Refract Corneal Surg. 1990;6:340–345
  19. van Haeringen NJ, Glasius E. The origin of some enzymes in tear fluid, determined by comparative investigation with two collection methods. Exp Eye Res. 1976;22:267–272
  20. Weimar V. Polymorphonuclear invasion of wounded corneas; inhibition by topically applied sodium salicylate and soybean trypsin inhibitor. J Exp Med. 1957;105:141–152Available at: http://www.jem.org/cgi/reprint/105/2/141Accessed March 11, 2008
  21. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways?. Immunol Today. 1997;18:415–417
  22. Hayashi K, Berman M, Smith D, El-Ghatit A, Pease S, Kenyon KR. Pathogenesis of corneal epithelial defects: role of plasminogen activator. Curr Eye Res. 1991;10:381–398
  23. Møller-Pedersen T, Li HF, Petroll WM, Cavanagh HD, Jester JV. Confocal microscopic characterization of wound repair after photorefractive keratectomy. Invest Ophthalmol Vis Sci. 1998;39:487–501Available at: http://www.iovs.org/cgi/reprint/39/3/487Accessed March 11, 2008
  24. Csutak A, Silver DM, Tőzsér J, Hassan Z, Berta A. Urokinase-type plasminogen activator to prevent haze after photorefractive keratectomy, and pregnancy as a risk factor for haze in rabbits. Invest Ophthalmol Vis Sci. 2004;45:1329–1333Available at: http://www.iovs.org/cgi/reprint/45/5/1329Accessed March 11, 2008

 Drs. Csutak, Silver, Tőzsér, and Berta are co-inventors of a patent describing the use of urokinase-type plasminogen activator to prevent haze after laser vision correction surgery. No other author has a financial or proprietary interest in any material or method mentioned.

 Supported in part by the Hungarian Scientific Research Fund, OTKA grants T38351 and F49055, and Hungarian Eötvös grant 9/2004, Hungary.

 Szilvia Pető, University of Debrecen, Medical and Health Science Center, Faculty of Medicine, provided technical assistance.

PII: S0886-3350(08)00294-0

doi: 10.1016/j.jcrs.2008.02.024

Journal of Cataract & Refractive Surgery
Volume 34, Issue 6 , Pages 897-901 , June 2008

Article Tools

* Image Usage & Resolution